Most Patients Prefer Oral Dual Therapy in Chronic Hepatitis C

This article originally appeared here.
Share this content:
Most Patients Prefer Oral Dual Therapy in Chronic Hepatitis C
Most Patients Prefer Oral Dual Therapy in Chronic Hepatitis C

MONDAY, Sept. 19, 2016 (HealthDay News) -- For patients with chronic hepatitis C (CHC), most prefer oral therapy with sofosbuvir (SOF) and ribavirin (RBV) versus triple therapy involving pegylated interferon (PegIFN), according to a study published online Sept. 14 in the Journal of Gastroenterology and Hepatology.

Sandeep Satsangi, from the Postgraduate Institute of Medical Education and Research in Chandigarh, India, and colleagues analyzed data from 158 patients with CHC treated with dual therapy (SOF + RBV) for 24 weeks or triple therapy (PegIFN + SOF + RBV) for 12 weeks.

The researchers found that the predominant genotype was genotype 3 (66.4 percent), followed by genotypes 1 and 4 (25.3 and 8.2 percent, respectively). Overall, 30.37 percent of patients had cirrhosis and 19 percent had received previous treatment with PegIFN + RBV. Within the cohort, 65.18 and 34.81 percent of patients received dual and triple therapy, respectively. Reasons for refusing triple therapy included resentment to receive injections, inaccessibility to a facility, fear of injection or its side effects, and financial constraints. All patients in the triple group and 98 percent in the dual therapy group attained end of treatment response (ETR). In both groups, all those who achieved ETR achieved sustained virological response at 12 weeks. Three patients (two in triple, one in dual therapy groups) had anemia; there were no other major side effects.

"Oral treatment with sofosbuvir plus ribavirin is preferred over interferon based triple therapy in patients with chronic hepatitis C," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NTproBNP Levels Are Significantly Lower in Blacks

NTproBNP Levels Are Significantly Lower in Blacks

Higher NTproBNP levels linked to increased risk of death; this association did not differ by race

Data May Weigh on Pros/Cons of Expanded Care Optometry

Data May Weigh on Pros/Cons of Expanded Care ...

Majority of residents in Kentucky, Oklahoma, New Mexico live within 30 minutes of ophthalmologist

Gaps Seen Between Hearing Loss, Receipt of Medical Evaluation, Tx

Gaps Seen Between Hearing Loss, Receipt of Medical ...

About 20.6 percent of those with hearing less than excellent/good had visited doctor for hearing issues

is free, fast, and customized just for you!

Already a member?

Sign In Now »